Genpharmasec (BOM:531592) Cyclically Adjusted PB Ratio: (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531592 Genpharmasec Ltd BOM:531592
58 GF Score
Price ₹1.16
GF Value ₹12.30
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Genpharmasec Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Genpharmasec  (BOM:531592) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genpharmasec Cyclically Adjusted PB Ratio Related Terms


Genpharmasec Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Genpharmasec's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genpharmasec Cyclically Adjusted PB Ratio Chart

Genpharmasec Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genpharmasec Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOM:531592 vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genpharmasec's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genpharmasec Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genpharmasec's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genpharmasec's Cyclically Adjusted PB Ratio falls into.


BOM:531592
58GF Score
Genpharmasec Ltd BOM:531592
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genpharmasec Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genpharmasec's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Genpharmasec's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Genpharmasec Quarterly Data

Book Value per Share CPI Adj_Book
201609 -1.711 105.961 -2.702
201612 0.000 105.196 0.000
201703 -1.674 105.196 -2.663
201706 0.000 107.109 0.000
201709 -1.655 109.021 -2.541
201712 0.000 109.404 0.000
201803 -1.591 109.786 -2.425
201806 0.000 111.317 0.000
201809 -1.387 115.142 -2.016
201812 0.000 115.142 0.000
201903 0.598 118.202 0.847
201906 0.000 120.880 0.000
201909 0.539 123.175 0.732
201912 0.000 126.235 0.000
202003 0.527 124.705 0.707
202006 0.000 127.000 0.000
202009 0.520 130.118 0.669
202012 0.000 130.889 0.000
202103 0.448 131.771 0.569
202106 0.000 134.084 0.000
202109 0.386 135.847 0.476
202112 0.000 138.161 0.000
202203 0.333 138.822 0.401
202206 0.000 142.347 0.000
202209 0.310 144.661 0.359
202212 0.000 145.763 0.000
202303 0.333 146.865 0.379
202306 0.000 150.280 0.000
202309 0.350 151.492 0.387
202312 0.000 152.924 0.000
202403 1.163 153.035 1.272
202406 0.000 155.789 0.000
202409 1.181 157.882 1.252
202412 0.000 158.323 0.000
202503 1.177 157.552 1.250
202506 0.000 159.755 0.000
202509 1.186 162.289 1.223
202512 0.000 163.281 0.000
202603 1.197 164.272 1.219
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Genpharmasec (BOM:531592) Overvalued in 2026?

Based on GuruFocus' analysis, Genpharmasec stock appears to be undervalued. The current stock price of ₹1.16 is trading 90.6% below its estimated GF Value™ of ₹12.30. GuruFocus considers Genpharmasec to be Possible Value Trap.

Key valuation signals for BOM:531592:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹12.30 vs. price of ₹1.16 (90.6% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the BOM:531592 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genpharmasec Business Description

Address Akurli Road, Office No. 104 and 105, 1st Floor, Gundecha Industrial Premises Co-op Soc. Ltd., Kandivali (East), Mumbai, MH, IND, 400101
Genpharmasec Ltd is engaged in pharmaceutical activities and services. The company operates in three reportable segments, namely: Diagnostic Pharma Equipment, Trading in Securities, and Laboratory Testing. The company generates the majority of its revenue from the Diagnostic Pharma Equipment Segment. Geographically, the company generates the majority of its revenue from the Domestic market.
58GF Score

Get the complete analysis for BOM:531592

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1.16
Price
₹12.30
GF Value